CompaniesInvestorsPeople
Home
Loading

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

  • Contact

  • Request a Demo

  • Request Data Updates

  • Add a Company

Research

  • Companies

  • Investors

  • People

aVenture

  • Download App

  • Pricing

Download the aVenture Research beta for iOS and iPadOSDownload aVenture Research on the Mac App Store

Resources

  • Documentation

  • Use Cases

  • CLI

  • MCP

  • Feature Requests

  • Sitemap

Member

Backed by

Ask AI about aVenture

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy · Terms of Service

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading
Home›
Companies›
Astraea›
Library
Astraea

Astraea

Astraea is an agentic AI platform that automates clinical-trial biometrics and regulatory submission deliverables for pharma sponsors.

Operating headquarters
San Francisco, CA, US🇺🇸
Founded
2026
Accelerator
Y Combinator logoY CombinatorX26
Loading
Overview
Analysis
Compare
Employees
News
Library

Astraea - Library

tryastraea.com·Crawled Oct 1, 2026·

Topics

Publication type

Content origin
Row density

Product

4 pages
  1. AI-Augmented FSP for Clinical Biometrics/solutions/embedded-teams

    Adopt Astraea inside your validated environment with an AI-Augmented FSP that operates the platform until your team owns the workflow.

  2. End-to-End Biometrics/solutions/end-to-end-biometrics

    Full-service biostatistics and programming from protocol design through NDA, BLA, and IND submissions, inspection-ready deliverables, FDA and EMA aligned.

  3. Platform/platform

    Clinical trial automation software for SAPs, SDTM/ADaM, TLFs, Define-XML, QC, and submission documents—inside your own environment.

  4. SDTM, ADaM & TLF Automation Software/solutions/standards-automation

    Automate SDTM and ADaM mapping, Define-XML, aCRFs, and TLF generation with human review and audit-ready traceability.

Comparison

4 pages
  1. Astraea vs. a CRO — Automated Biometrics/astraea-vs-cro

    Astraea vs. a traditional CRO: sponsor-run software that automates post-protocol work through submission, with your statisticians approving every output.

  2. Astraea vs. Koneksa Lodestar: Submission Software/astraea-vs-koneksa

    Astraea vs. Koneksa Lodestar: compare workflow scope, early-access availability, benchmark evidence, and Astraea's in-environment deployment model.

  3. Astraea vs. Saama: In-Environment vs. Cloud AI/astraea-vs-saama

    Astraea vs. Saama: compare cloud clinical data software with sponsor-run automation deployed inside your own environment, from SAP through submission.

  4. Astraea vs. TriClick Software & Hill Research Services/astraea-vs-hill-research

    Compare Astraea with TriClick software and, separately, Hill Research's project-based biostatistics and FSP services using current first-party evidence.

About

1 page
  1. About/about

    Sponsor-run clinical trial automation software installed inside customer environments, built by biostatisticians, clinical programmers, and sponsor-side leaders.

Contact

1 page
  1. Contact/contact

    Book a demo to see how Astraea compresses your biometrics and submission timeline. Talk to the team about your study—we reply within one business day.

Homepage

2 pages
  1. Homepage/

    Astraea automates SAPs, SDTM/ADaM, TLFs, Define-XML, QC, and FDA submission documents inside your environment. Sponsor-run software, not a CRO.

  2. Homepage/

    Astraea automates SAPs, SDTM/ADaM, TLFs, Define-XML, QC, and FDA submission documents inside your environment. Sponsor-run software, not a CRO.

Privacy

1 page
  1. Privacy/privacy

    How Astraea collects, uses, and safeguards personal information across our website and clinical trial automation platform.

Terms & Conditions

1 page
  1. Terms/terms

    The terms that govern your use of the Astraea website, platform, and related services — acceptable use, customer data, compliance, and liability.

Coverage

4 items
  1. Astraea: YC P26 company automating clinical trial biometricsyctierlist.com/s26/astraea/

    Astraea targets automation of clinical trial biometrics for Phase II/III sponsors. YC Tier List rates it B-tier among Spring 2026 Y Combinator companies.

    Jun 2026 · YC Tier ListNews article

  2. Astraea (YC P26) has completely automated clinical trial biometricslinkedin.com/posts/y-combinator_astraea-yc-p26-has-completely-automated-activity-7460811187241275394-Rkw5

    Astraea (YC P26) has automated the clinical trial biometrics pipeline. The company helps pharma teams turn raw clinical data into FDA-ready packages in days.

    Apr 2026 · LinkedIn / Y CombinatorNews article

  3. Astraea (YC P26) is part of the Y Combinator spring 26 batchlinkedin.com/posts/joshua-wang-229196319_astraea-yc-p26-is-part-of-the-y-combinator-activity-7453230365420212224-gCH2

    Astraea joins Y Combinator’s Spring 2026 batch, co-founder Joshua Wang announces. The company is working to automate the biometrics pipeline for pharma teams.

    Apr 2026 · LinkedIn / Joshua WangNews article

  4. Astraea - Agents Accelerating clinical trialsycombinator.com/launches/QLz-astraea-agents-accelerating-clinical-trials

    Astraea launches on Y Combinator with an agentic platform that automates clinical trial data analysis and statistical programming. The platform generates CDISC-compliant datasets, TFLs, and FDA-ready outputs.

    Apr 2026 · Y Combinator LaunchesNews article